Subgroup analysis of phase 2 study of ceftolozane/tazobactam in neonates and young infants with pyelonephritis

Ceftolozane/tazobactam is approved for the treatment of patients from birth to

Saved in:
Bibliographic Details
Published in:Microbiology spectrum 2023-10, Vol.11 (5), p.e0180023-e0180023
Main Authors: Roilides, Emmanuel, Bradley, John S., Lonchar, Julia, Huntington, Jennifer A., Wickremasingha, Prachi, Su, Feng-Hsiu, Bruno, Christopher J., Johnson, Matthew G.
Format: Article
Language:English
Subjects:
ceftolozane/tazobactam
cUTI
neonates
pyelonephritis
young infants
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Ceftolozane/tazobactam is approved for the treatment of patients from birth to
ISSN:2165-0497
2165-0497
DOI:10.1128/spectrum.01800-23